Hematolojik Maligniteli Hastalarda Parvovirus B19 Varlığının Araştırılması

Year 2012, Volume: 5 Issue: 3, 24 - 29, 01.09.2012

Şaban Gümüştekin Seda Tezcan Mahmut Ülger Naci Tiftik Mehmet Sami Serin Gönül Aslan Gürol Emekdaş

Abstract

Abstract An Investigation on the Presence of Parvovirus B19 in The Patients with Hematological Malignancies Aim: Parvovirus B19 is associated with a wide range of diseases in human, whose severity depends on the immunological and haematological status of the host. In this study, the aim was set to determine the presence of parvovirus B19 DNA and the assessment of the prevalance among patients suffering from different haematological malignancies and healty blood donors. Method: In this study, the plasma samples of 100 patients with hematological malignancy and 104 healthy blood donors were investigated for the presence of parvovirus B19 DNA (PV-B19 DNA) by polymerase chain reaction method. Results: Parvovirus B19 DNA was detected in the 20 (20%) of 100 patients with hematologic malignancies and 8 (7.7%) of 104 healthy blood donors and the difference was found to be statistically significant (p=0.018). In addition, the rate of parvovirus B19 DNA positivity was16.5% in the patients with chronic leukemia (chronic lymphocytic leukemia and chronic myeloid leukemia) and 4.4% in those with acute leukemia (acute lymphocytic leukemia and acute myeloid leukemia). The difference between these two groups of leukemia patients was also found statistically significant (p=0.0153). Conclusion: As a result of this study, the presence of parvovirus B19 study in the patients with hematological malignancies was found higher than in healthy individuals. Based on the data obtained in this study, the high positivity ratio in the patients with chronic leukemia in comparison to the ones with acute leukemia may be an indicator of persistent parvovirus B19 infection. On the other hand, the relatively high parvovirus B19 DNA positivity in blood donors possesses vital significance for the hematological patients in need of blood transfusion.

Keywords

Parvovirus B19; hematological malignancies; blood donors; polymerase chain reactio

Hematolojik Maligniteli Hastalarda Parvovirus B19 Varlığının Araştırılması

Abstract

Türkçe Özet: Amaç: Parvovirus B19, insanlarda ciddiyeti konağın immünolojik ve hematolojik durumuna bağlı olarak çok çeşitli hastalıklar ile ilişkilidir. Bu çalışmada, değişik hematolojik maligniteli hastalar ve sağlıklı kan bağışçılarında parvovirus B19 DNA\'sının belirlenmesi ve prevalansının değerlendirilmesi amaçlandı. Yöntem: Çalışmada, hematolojik maligniteli 100 hasta ve 104 sağlıklı kan bağışçısına ait plazma örneklerinde parvovirus B19 DNA varlığı polimeraz zincir reaksiyonu yöntemi ile araştırıldı. Bulgular: Hematolojik maligniteli 100 hastanın 20 (%20)\'sinde, 104 sağlıklı kan bağışçısının 8 (%7.7)\'inde parvovirus B19 DNA\'sı tespit edildi ve aradaki fark istatistiksel olarak anlamlı bulundu (p=0.018). Ayrıca, parvovirus B19 DNA\'sı kronik lösemili hastalarda (kronik lenfoblastik lösemi ve kronik miyeloid lösemi) %16.5, akut lösemili hastalarda (akut lenfoblastik lösemi ve akut miyeloid lösemi) %4.4 olarak saptandı ve aradaki fark istatistiksel olarak anlamlı bulundu (p=0.0153). Sonuç: Sonuç olarak, çalışmada hematolojik maligniteli hastalarda parvovirus B19 varlığı, sağlıklı bireylere oranla daha yüksek bulunmuştur. Çalışmada akut lösemili gruba göre kronik lösemili gruptaki yüksek pozitiflik oranı bu hastalarda persistan parvovirus B19 infeksiyonunun bir göstergesi olabilir. Diğer yandan kan bağışçılarındaki nispeten yüksek parvovirus B19 DNA pozitifliği, kan transfüzyonu yapılacak hematolojik hasta grupları için hayati önem taşımaktadır.

Keywords

Parvovirus B19; hematolojik malignite; kan bağışçıları; polimeraz zincir reaksiyonu

References

• Heegaard ED, Brown KE. Human parvovirus Bl9. Clin Microbiol Rev 2002;15(3):485-505.
• Gadage VS, Viswanathan S, Kunal S, Subramanian PG, Gujral S. Parvovirus B19 presenting with persistent pancytopenia in a patient of T-ALL post induction chemotherapy diagnosed on bone marrow examination. Indian JPathol Microbial 2011;54(3):603-5.
• Bassols AC. Parvovirus B19 and the new century. Clin Infect Dis 2008;46(4):537-9.
• Kerr JR, Barah F, Cunniffe VS, Smith J, Vallely PJ, Will AM, Wynn RF, Stevens RF, Taylor GM, Cleator GM, Eden OB. Association of acute parvovirus B19 infection with new onset of acute lymphoblastic and myeloblastic leukaemia. J Clin Pathol 2003;56(11):873-5.
• Zaki SA. Detection of human parvovirus B19 in cancer patients using ELISA and real-time PCR. Indian J Med Microbial 2012;30(4):407-10.
• Sambrook J, Fritsch EF, Maniatis T. Maleculer Cloning: A Laboratory Manuel, Book 3, 2“1 Ed., New York: Cold Spring Harbor Laboratory Press, 1989:213-300.
• Sifakis S, Ergazaki M, Sourvinos G, Koffa M, Koumantakis E, Spandidos DA. Evaluation of Parvo Bl9, CMV and HPV viruses in human aborted material using the polymerase chain reaction technique. Eur J Obstet Gynecol Reprod Biol l998;76(2):169-73.
• Brown KE. The expanding range of parvoviruses which
• infect humans. Rev Med Virol 2010;20(4):231-44.
• Yetkin S, Elmas SA. Parvovirus-319 and hematologic
• disorders. Turk J Hematol 2010;27(l):224-33.
• Bonvicini F, Manaresi E, Di Furio F, De Falco L, Gallinella
• G. Parvovirus bl 9 DNA CpG dinucleotide methylation and
• Yalcin A, Serin MS, Emekdas G, Tiftik N, Aslan G,
• Eskandari G, Tezcan S. Promoter methylation of
• Kishorc J, Sen M, Kumar A, Kumar A. A pilot study on
• parvovirus B19 infection in paediatric haematological malignancies. Indian J Med Res 2011;133(4):407-13.
• da Costa AC, Bendit I, de Oliveira AC, Kallas EG, Sabino
• EC, Sanabani SS. Investigation of human parvovirus Bl9
• Us T, Ozune L, Kasifoglu N, Akgun Y. The investigation of
• parvovirus B19 infection in patients with haematological disorders by using PCR and ELISA techniques. Braz J Infect 2007; 1 1(3):327-30.
• Hematolojik Hastalarda Parvovı'rus 319 Varlığı
• Zaki ME, Ashray RE. Clinical and hematological study for
• Parvovirus B19 infection in children with acute leukemia.
• Jitschin R, Peters O, Plentz A, Turowski P, Segerer H,
• Modrow S. Impact of parvovirus B19 infection on
• El-Mahallawy HA, Mansour T, El-Din SE, Hafez M, Abd
• el-Latif S. Parvovirus B 19 infection as a cause of anemia in pediatric acute lymphoblastic leukemia patients during maintenance chemotherapy. J Pediatr Hematol Oneal 2004;26(7):403-6.
• Plentz A, Hahn J, Knoll A, Holler E, Jilg W, Modrow S.
• Exposure of hematologic patients to parvovirus B19 as a
• Satake M, HoshiY, Taira R, Momose SY, Hino S, Tadokoro
• K. Symptomatic parvovirus B19 infection caused by blood
• Işık N, Sabahoglu E, Işık DM, Anak S, AgacŞdan A,
• Bozkaya E. Klinik Olarak Parvovirus B19 lnfeksiyonu On Tanili Olguların Virolojik Takibi. Turk Mikrobiyol Cem Derg 2004;34(1):62-6.